Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-18T21:00:28.408Z Has data issue: false hasContentIssue false

FC01-03 - Deep Brain Stimulation Of Subcallosal Cingulate Gyrus for Treatment Resistant Depression

Published online by Cambridge University Press:  17 April 2020

D. Puigdemont
Affiliation:
Psychiatry, Hospital de la Santa Creu i Sant Pau. CIBERSAM, Barcelona, Spain
M.J. Portella
Affiliation:
Psychiatry, Hospital de la Santa Creu i Sant Pau. CIBERSAM, Barcelona, Spain
R. Pérez-Egea
Affiliation:
Psychiatry, Hospital de la Santa Creu i Sant Pau. CIBERSAM, Barcelona, Spain
J. Radua
Affiliation:
CRC CIM / Neurosciences Imaging Group, Parc de Recerca en Biomedicina de Barcelona, Barcelona, Spain
J. de Diego-Adeliño
Affiliation:
Psychiatry, Hospital de la Santa Creu i Sant Pau. CIBERSAM, Barcelona, Spain
J. Molet
Affiliation:
Neurosurgery, Barcelona, Spain
A. Gironell
Affiliation:
Neurology, Hospital de la Santa Creu i Sant Pau. Universitat Autònoma de Barcelona, Barcelona, Spain
E. Alvarez
Affiliation:
Psychiatry, Hospital de la Santa Creu i Sant Pau. CIBERSAM, Barcelona, Spain
V. Pérez
Affiliation:
Psychiatry, Hospital de la Santa Creu i Sant Pau. CIBERSAM, Barcelona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background

Deep brain stimulation (DBS) of the subcallosal cingulate gyrus (SCG) has been suggested to improve depressive symptoms in treatment-resistant depression (TRD). We now report preliminary results of DBS and one-year follow up in six patients.

Methods

Six patients with severe TRD (Thase Resistance Index>4) underwent DBS surgery and subsequent monthly assessments. DBS response was defined as ≥50% reduction in the 17-item Hamilton Depression Rating Scale (HDRS) or HDRS< 8 (remission). Electrodes location was assessed in each patient by means of pre/post-DBS MRIs co-registration.

Results

DBS led to early and late reductions of average HDRS (from 22.5 to 9.8 and 6.25 respectively, see Figure 1 for evolution of HDRS mean scores). One month after surgery 16.7% of patients met criteria for response and for remission. Three months after response rates increased to 66.7% while remission rates were maintained. At six months, 66.7% of patients were responders. After 9 months, response rates arose up to 83.4% and these rates were largely maintained at 12 months. Remission rates showed similar growth over follow-up. No substantial differences were observed in electrodes location, and they were not found to be related to response or remission rates. The number of serious adverse effects was small with no patient experiencing permanent deficits.

Conclusions

This study suggests that DBS is relatively safe and provides significant improvement in patients with TRD. Improvement on average seems to be linearly progressive and, once melioration is achieved, it is maintained for at least one year. The procedure is well tolerated.

Type
Free Communications
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.